Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) have been given a consensus rating of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.67.

GNMK has been the topic of several analyst reports. BidaskClub downgraded shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, March 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of GenMark Diagnostics in a report on Friday, February 22nd. Zacks Investment Research downgraded shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, February 12th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $10.00 target price on shares of GenMark Diagnostics in a report on Wednesday, May 1st.

GenMark Diagnostics stock traded up $0.08 during midday trading on Friday, hitting $7.00. 5,645 shares of the company’s stock were exchanged, compared to its average volume of 337,876. GenMark Diagnostics has a 12-month low of $3.58 and a 12-month high of $8.81. The company has a debt-to-equity ratio of 1.96, a quick ratio of 3.40 and a current ratio of 3.93. The company has a market capitalization of $391.80 million, a P/E ratio of -7.73 and a beta of 1.47.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). GenMark Diagnostics had a negative return on equity of 137.04% and a negative net margin of 71.40%. The business had revenue of $21.53 million for the quarter, compared to analysts’ expectations of $21.08 million. As a group, equities analysts expect that GenMark Diagnostics will post -0.81 earnings per share for the current year.

In other news, SVP Michael Gleeson sold 10,000 shares of GenMark Diagnostics stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $7.51, for a total value of $75,100.00. Following the sale, the senior vice president now owns 373,101 shares of the company’s stock, valued at $2,801,988.51. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Hany Massarany sold 6,247 shares of GenMark Diagnostics stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $6.62, for a total transaction of $41,355.14. Following the completion of the sale, the insider now directly owns 835,320 shares in the company, valued at approximately $5,529,818.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,847 shares of company stock worth $395,743. Insiders own 5.24% of the company’s stock.

Several large investors have recently modified their holdings of GNMK. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of GenMark Diagnostics by 123.3% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,466 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 2,466 shares in the last quarter. Ameritas Investment Corp purchased a new stake in GenMark Diagnostics during the first quarter worth about $43,000. Legal & General Group Plc boosted its holdings in GenMark Diagnostics by 48.6% during the fourth quarter. Legal & General Group Plc now owns 11,308 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 3,700 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in GenMark Diagnostics by 56,694.7% during the first quarter. BNP Paribas Arbitrage SA now owns 10,791 shares of the medical equipment provider’s stock worth $77,000 after buying an additional 10,772 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in GenMark Diagnostics during the fourth quarter worth about $80,000. 91.07% of the stock is currently owned by institutional investors and hedge funds.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.